MX9303082A - Proteasa y componentes relacionados con el dna. - Google Patents

Proteasa y componentes relacionados con el dna.

Info

Publication number
MX9303082A
MX9303082A MX9303082A MX9303082A MX9303082A MX 9303082 A MX9303082 A MX 9303082A MX 9303082 A MX9303082 A MX 9303082A MX 9303082 A MX9303082 A MX 9303082A MX 9303082 A MX9303082 A MX 9303082A
Authority
MX
Mexico
Prior art keywords
protease
dna
related components
compounds
provides
Prior art date
Application number
MX9303082A
Other languages
English (en)
Inventor
Franklin Harpold Norris
Eric Paul Dixon
Edward Marion Johnstone
Sheila Parks Little
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9303082A publication Critical patent/MX9303082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • External Artificial Organs (AREA)

Abstract

Esta invención proporciona una proteína de desdoblamiento de APP y compuestos relacionados. La invención también proporciona métodos, materiales y ensayos. Los compuestos de esta invención proporcionarán la caracterización de enfermedades neurológicas tales como la enfermedad de Alzheimer y el síndrome de Down.
MX9303082A 1992-05-28 1993-05-26 Proteasa y componentes relacionados con el dna. MX9303082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89154292A 1992-05-28 1992-05-28

Publications (1)

Publication Number Publication Date
MX9303082A true MX9303082A (es) 1994-06-30

Family

ID=25398377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303082A MX9303082A (es) 1992-05-28 1993-05-26 Proteasa y componentes relacionados con el dna.

Country Status (17)

Country Link
US (1) US5733768A (es)
EP (1) EP0576152B1 (es)
JP (1) JP3568552B2 (es)
KR (1) KR930023465A (es)
AT (1) ATE227343T1 (es)
AU (1) AU670080B2 (es)
BR (1) BR9302075A (es)
CA (1) CA2096911C (es)
CZ (1) CZ98293A3 (es)
DE (1) DE69332462T2 (es)
ES (1) ES2185621T3 (es)
FI (1) FI932425L (es)
HU (1) HUT69612A (es)
IL (1) IL105793A0 (es)
MX (1) MX9303082A (es)
NO (1) NO931889L (es)
PL (1) PL299053A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531586B1 (en) 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
US6210919B1 (en) 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6329163B1 (en) 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
AU4480797A (en) * 1996-09-13 1998-04-02 Dana-Farber Cancer Institute Protease m, a novel serine protease
CA2330242A1 (fr) * 1998-06-05 1999-12-16 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
FR2779444A1 (fr) * 1998-06-05 1999-12-10 Rhone Poulenc Rorer Sa Polypeptides possedant une activite de type beta-secretase et capables de cliver le precurseur naturel du peptide beta-amyloide (app)
WO2000001807A1 (en) * 1998-07-02 2000-01-13 Fuso Pharmaceutical Industries, Ltd. Serine protease-specific monoclonal antibody and utilization thereof
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
NZ510708A (en) * 1998-09-24 2003-12-19 Upjohn Co Alzheimer's disease and Asp1 and Asp2 cleaving APP site (beta secretase)
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
HK1044545A1 (zh) 1999-02-10 2002-10-25 Elan Pharmaceuticals, Inc. 贝他分泌酶组合物及其方法
US20020049303A1 (en) * 1999-06-28 2002-04-25 Tang Jordan J. N. Catalytically active recombinant memapsin and methods of use thereof
EP1194449B1 (en) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
CA2360219A1 (en) 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
EP1330652B1 (en) * 2000-10-27 2007-06-27 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
AU2002359301B2 (en) * 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
US20050106586A1 (en) * 2003-06-13 2005-05-19 Mount Sinai Hospital Detection of neurodegenerative diseases
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62312A (en) * 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
HUT69771A (en) * 1990-08-17 1995-09-28 Univ Boston Proteases causing abnormal degradation of amyloid beta-proteine precursors
US5292652A (en) * 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof

Also Published As

Publication number Publication date
KR930023465A (ko) 1993-12-18
AU670080B2 (en) 1996-07-04
CZ98293A3 (en) 1994-02-16
DE69332462D1 (de) 2002-12-12
EP0576152A1 (en) 1993-12-29
ES2185621T3 (es) 2003-05-01
HU9301557D0 (en) 1993-10-28
NO931889D0 (no) 1993-05-25
NO931889L (no) 1993-11-29
BR9302075A (pt) 1993-11-30
FI932425A7 (fi) 1993-11-29
DE69332462T2 (de) 2003-07-10
US5733768A (en) 1998-03-31
HUT69612A (en) 1995-09-28
PL299053A1 (en) 1994-02-21
IL105793A0 (en) 1993-09-22
FI932425L (fi) 1993-11-29
EP0576152B1 (en) 2002-11-06
CA2096911C (en) 2004-11-02
CA2096911A1 (en) 1993-11-29
ATE227343T1 (de) 2002-11-15
FI932425A0 (fi) 1993-05-27
JPH0662855A (ja) 1994-03-08
AU3986493A (en) 1993-12-02
JP3568552B2 (ja) 2004-09-22

Similar Documents

Publication Publication Date Title
MX9303082A (es) Proteasa y componentes relacionados con el dna.
FI944412A0 (fi) Proteiinin puhdistus
ATE507839T1 (de) Kombinationstherapie
ATE322505T1 (de) Tgf-g beta inhibitor-peptide
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
NO994998L (no) Fusjonsproteiner
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
NO20005548L (no) Mykobakterieinhibitorer
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
ECSP972266A (es) Terapia de combinacion para el tratamiento de psicosis
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.